Tag: IHL-42X

All

Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA

The crossover dose optimization study aims to refine the dosing profile of the oral therapy and strengthen the design of the planned phase III development program.

Incannex Forms Clinical Advisory Board to Guide IHL-42X Sleep Apnea Drug Development
Incannex Reports Positive Data for OSA Drug Candidate IHL-42X
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials
Incannex Completes Dosing in Trial for Sleep Apnea Drug Candidate IHL-42X
Patient Dosing Begins in Phase 2/3 Trial for OSA Drug Candidate IHL-42X
‘Truly Remarkable’ Results Spur Incannex’s Phase 2/3 Trials for Sleep Apnea Drug Candidate, Says CEO

All

Initiation of Phase 2/3 Trial Underway for OSA Drug Candidate IHL-42X

To further assess the safety and efficacy of IHL-42X in patients with OSA, Incannex is conducting a phase 2/3 clinical trial that will be conducted at 55 sites across the United States, Europe, and other countries.